Last Updated: May 10, 2026

Profile for Peru Patent: 20080349


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Peru Patent: 20080349

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Key insights for pharmaceutical patentability - Peru patent PE20080349

Last updated: April 24, 2026

Peru PE20080349: Scope, Claims, and Patent Landscape

What does PE20080349 cover?

PE20080349 is a Peruvian patent publication granted from an application filed in the 2008–2009 window. The record identifies a therapeutic pharmaceutical invention, but the public-facing scope summary does not include the full claim set in the material available here. Because claim text is not provided, a complete, text-accurate claim chart (independent and dependent claims, every limitation, and claim-by-claim scope boundaries) cannot be produced.

What is the claim scope based on?

A reliable scope analysis for a drug patent requires the exact language of:

  • Independent claims (active ingredient definition, salt/polymorph rules, formulation elements, dosing regimen boundaries, and process parameters if claims are manufacturing-based)
  • Dependent claims (preferred embodiments, specific excipients, dosage ranges, particle size, release profiles, manufacturing steps)
  • Product-by-process versus pure product delimiters
  • Priority/filing dates and whether the claims are constrained by the examples

Those elements are not available in the provided materials, so the claim scope cannot be reconstructed without risking inaccuracies.

How does PE20080349 fit the Peruvian patent landscape?

A correct landscape requires, at minimum:

  • CPC/IPC families tied to PE20080349
  • Citation and forward-citation clusters in Peru (and related jurisdictions)
  • Status outcomes (granted/expired/lapsed) for close family members in Peru
  • Linkage to Peru’s local regulatory exclusivity or patent term adjustments (where applicable)

The needed bibliographic and legal-status data for PE20080349 and its close family set is not present in the available content here. As a result, the landscape cannot be mapped with proof-grade specificity.


PE20080349: Scope Analysis (what can be stated without claim text)

1) Legal relevance

  • PE20080349 is a Peruvian drug patent publication identified by the number “PE20080349.”
  • It has enough procedural history to be part of Peru’s national patent documentation and to support enforceability and freedom-to-operate analysis only if claims are consulted in full.

2) Practical enforcement posture

Without the exact claim set, enforcement posture in Peru cannot be stated in claim-accurate terms. In particular, the following cannot be validated:

  • Whether the claims are limited to a specific molecule (and which salt form)
  • Whether the claims cover a formulation only (e.g., tablet/capsule composition, excipient system, release profile)
  • Whether regimen claims exist (dose amount, frequency, duration)
  • Whether manufacturing/process claims exist that could be implicated by generic process design

Patent Landscape Framework (how the competitive map should be built for PE20080349)

The landscape for a drug patent in Peru is typically built through three evidence layers:

A) Family and claim-set comparability

  • Identify the priority application(s) and the closest family members by INPADOC/Families and publication equivalents.
  • Compare claim boundaries across jurisdictions to understand which features are “core” versus jurisdiction-specific narrowing.

B) Peru-specific legal status

  • Check whether PE20080349 is granted and whether it remains in force.
  • Identify any legal events: term adjustments, lapses, terminal disclaimers, or re-examination outcomes if they exist in the record.

C) Competitive encroachment channels

  • Identify generic entry signals in Peru (filings, approvals, or regulatory actions).
  • Track whether competitors target:
    • same API but different salt/polymorph
    • same formulation but different excipient matrix
    • same regimen but different dose units
    • different release profile or manufacturing route

Why a claim-by-claim landscape is not deliverable here

A “detailed analysis of the scope and claims” must use the actual claim language. The requirement for actionable outcomes in Peru depends on text-level limitations. The available prompt does not include:

  • the claim text for PE20080349
  • the bibliographic description sufficient to identify the exact invention subject matter
  • the legal status record and citation graph needed for landscape mapping

Producing a detailed scope or landscape anyway would require guessing the API, salt/form, dosage, or formulation, which would not be proof-grade for investment or R&D decisions.


Key Takeaways

  • PE20080349 is identifiable as a Peruvian drug patent publication, but the claim text and legal-status details are not available in the provided material needed for a complete scope and claims analysis.
  • A proof-grade Peru landscape for PE20080349 requires the full claim set, family mapping, and Peru status events, none of which are present here.
  • A reliable deliverable for business use (claim chart, infringement boundaries, generic/competitor encroachment map) cannot be generated without the missing claim and legal record content.

FAQs

1) What does “scope of claims” mean for a Peruvian drug patent?

It is the set of technical and legal limitations in the independent and dependent claims that define what products or methods fall inside or outside infringement in Peru.

2) Can a landscape be done without claim text?

A high-level landscape can sometimes be drafted from bibliographic data, but claim-accurate scope, design-around options, and enforceability analysis require the actual claim language.

3) Does Peru enforce patent claims the same way across product and process inventions?

Enforcement typically depends on whether claims are product-defined, process-defined, or product-by-process, and on the exact delimiting language in the claims.

4) What evidence matters most for freedom-to-operate around a Peru drug patent?

Patent claim text, current legal status (in force vs lapsed), family claim variations, and any regulatory entry evidence that suggests competitor target features.

5) How should a PE-number patent be positioned in a competitive map?

By tying PE publication to its claim family and then filtering for Peru-specific status and the competitor strategies that map to the claim limitations.


References

[1] WIPO. PATENTSCOPE database (Peru national/regional collection). https://patentscope.wipo.int/
[2] INPADOC / EPO patent family and legal status tools (via public portals). https://www.epo.org/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.